Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2007

RXi Obtains Rights to Cold Spring Harbor shRNAi Technology

  • RXi Pharmaceuticals secured a nonexclusive, worldwide research and therapeutic license from Cold Spring Harbor Laboratory to their shRNAi technology. The licensed technology potentially allows for the more efficient triggering of RNAi and includes the use of shRNAi either delivered as RNA compositions or encoded by DNA constructs. Patents covering this technology are currently pending. 

    "With this license for all human therapeutic areas, we gain the well-validated advantage of shRNAi—which is reported to be up to 10- to 100-fold more potent compared with standard siRNA," says Tod Woolf, Ph.D., RXi's president and CEO.

    The technology licensed by RXi was developed in the laboratory of Gregory J. Hannon, Ph.D., a Howard Hughes Medical Institute Investigator at Cold Spring Harbor Laboratory.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »